The Comparison of Cataract Lasers Using the Optimedica Catalys Laser and the Alcon LenSx Laser.
Launched by STEVEN H. LINN, OD · Jun 13, 2013
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
The purpose of this study is to systematically evaluate the performance of two commercially available and FDA cleared femtosecond laser systems in patients undergoing femtosecond laser-assisted cataract surgery. Objective data on the repeatability and accuracy of the studied parameters will be gathered and reported as endpoints of the study.
The two systems studied are the Catalys™ Precision Laser System (OptiMedica, CA, USA) and the LenSx® Laser System (Alcon Laboratories, Inc., Fort Worth, TX).
Published data have suggested that the femtosecond laser is a useful tool for cataract surger...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have grade 2 to 4 nuclear sclerotic and or cortical or posterior subcapsular cataracts with visual impairment.
- • Pupillary dilation of at least 6.0 mm
- • Axial length between 21 mm to 26 mm
- • Age ≥ 22 years of either gender
- • Require laser assisted corneal incisions, capsulotomy and nucleus segmentation
- • Understand and sign a written Informed Consent form
- • Be able to comply with the treatment and follow-up schedule
- Exclusion Criteria:
- • Enrolment in another drug or device study within the prior 3 months
- • History of ocular trauma
- • Acute or chronic disease or illness that would increase risk or confound study results (e.g., uncontrolled diabetes mellitus, immunocompromised, etc.)
- • Uncontrolled systemic or ocular disease
- • Corneal abnormalities (e.g., stromal, epithelial or endothelial dystrophies, severe corneal opacities, significant corneal edema, etc)
- • Diminished aqueous clarity that obscures OCT imaging of the anterior lens capsule
- • Corneal ring and/or inlay implant(s)
- • Pseudoexfoliation
- • Known steroid IOP responder or ocular hypertension IOP \>25 mmHg by tonometry
- • Retinal detachment within the last 6 months
- • Anterior chamber depth less than 2.5 mm
About Steven H. Linn, Od
Steven H. Linn, OD, is a dedicated clinical trial sponsor with a focus on advancing eye care research and improving patient outcomes through innovative studies. With extensive experience in optometry and a commitment to clinical excellence, Dr. Linn leads initiatives aimed at evaluating cutting-edge treatments and interventions in ocular health. His work emphasizes collaboration with healthcare professionals, regulatory bodies, and research institutions to ensure rigorous study design, ethical standards, and comprehensive data analysis, ultimately contributing to the enhancement of clinical practices in the field of optometry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salt Lake City, Utah, United States
Patients applied
Trial Officials
Robert P Rivera, MD
Principal Investigator
Hoopes Vision
Steven H Linn, OD
Study Director
Hoopes Vision
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials